Abstract 426P
Background
The support for caregivers (CG) of patients with cancer is an essential factor for maintaining the safety and continuity of palliative chemotherapy. Because of insufficient knowledge regarding their QOL, there are no durable strategies for supporting CGs during the treatment.
Methods
We aimed to assess the QOL of the CGs of patients with cancer undergoing palliative chemotherapy. This single-institution, prospective, observational study was approvedby the institutional review board of Ina Central Hospital on July 20th 2016. Total 102 patients undergoing palliative chemotherapy (64 male and 38 female patients; mean age 68.8 years) and their CGs (30 maleand 72 female; mean age 64.3 years) were included. The primary lesions in the patients were pancreatic in 30, colorectal in 21, stomach or duodenal in 21, oesophageal in 18, and biliary in 12. We used EORTC QL-C-30 to assess the QOL of patients and CGs at the beginning of the first-line chemotherapy. A total of 29 of 102 pairs of patients and CGs were assessed at the beginning of the first and second-line chemotherapies. According to a formula incorporating measures of clinical symptoms and comprehensive scales of physical function (PF), role function (RF), emotional function (EF), cognitive function (CF), and social function. In addition, a summary score (SS) and a global health scale (GHS) on QOL were computed using comprehensive scales.
Results
All the parameters assessed in CGs yielded higher values than those for patients; however, EF and CF did not show significant differences between patients and CGs. Among longitudinal observed pairs, discrepancies in GHS and SS between patients and CGs were identified in 38 % and 34%, respectively. Those CGs who did not demonstrate an improvement in GHS compared with those who showed an improvement in this parameter had lower PF and RF values at the beginning of the treatment.
Conclusions
Even at the beginning of the treatment, the CGs of patients with cancer undergoing palliative chemotherapy showed impairment in daily QOL. In addition, emotional and cognitive functions were impaired as much as patients. CGs with physical difficulty and role function impairment in family should be monitored for worsening of their QOL during the course of treatment.
Clinical trial identification
Editorial acknowledgement
This has been edited for English language, grammar, punctuation, and spelling by Enago, the editing brand of Crimson Interactive Pvt. Ltd under Normal Editing.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract